MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy

Citation: Valera A, López-Guillermo A, Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S, Espinosa I, Novelli S, Briones J, Mate JL, Salamero O, Sancho JM, Arenillas L, Serrano S, Erill N, Martínez D, Castillo P, Rovira J, Martínez A, Campo E, and Colomo L. MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica. 2013; 98:xxx doi:10.3324/haematol.2013.086173

[1]  A. Rosenwald,et al.  MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. , 2013, Blood.

[2]  L. Staudt,et al.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Benekli,et al.  Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B‐cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab , 2012, Cancer.

[4]  R. Spang,et al.  High myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas , 2012, International journal of cancer.

[5]  K. Young,et al.  Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Monti,et al.  Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas , 2012, PloS one.

[7]  K. Young,et al.  High Levels of Nuclear MYC Protein Predict the Presence of MYC Rearrangement in Diffuse Large B-cell Lymphoma , 2012, The American journal of surgical pathology.

[8]  E. Jaffe,et al.  Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. , 2011, Hematology. American Society of Hematology. Education Program.

[9]  A. Ariza,et al.  Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas , 2011, Histopathology.

[10]  W. Chan,et al.  Gains of MYC locus and outcome in patients with diffuse large B‐cell lymphoma treated with R‐CHOP , 2011, British journal of haematology.

[11]  M. Neat,et al.  Fluorescence in situ hybridisation analysis of formalin-fixed paraffin-embedded tissue sections in the diagnostic work-up of non-Burkitt high grade B-cell non-Hodgkin's lymphoma: a single centre's experience , 2011, Journal of Clinical Pathology.

[12]  Elias Campo,et al.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. , 2011, Blood.

[13]  R. Siebert,et al.  The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Giné,et al.  Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. , 2011, Blood.

[15]  R. Gascoyne,et al.  MYC and Aggressive B-cell Lymphomas , 2011, Advances in anatomic pathology.

[16]  Philip M Kluin,et al.  Double-hit B-cell lymphomas. , 2011, Blood.

[17]  L. Colomo,et al.  IG/MYC Rearrangements are the Main Cytogenetic Alteration in Plasmablastic Lymphomas , 2010, The American journal of surgical pathology.

[18]  E. Giné,et al.  Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior , 2010, Haematologica.

[19]  S. Barrans,et al.  Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Dirk Hasenclever,et al.  Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Rimsza,et al.  Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma , 2010, Haematologica.

[22]  Matija Snuderl,et al.  B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma , 2010, The American journal of surgical pathology.

[23]  C. Copie-Bergman,et al.  Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Gascoyne,et al.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.

[25]  I. Miura,et al.  Clinical significance of 8q24/c‐MYC translocation in diffuse large B‐cell lymphoma , 2009, Cancer science.

[26]  A. Rosenwald,et al.  Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) , 2008, Leukemia.

[27]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[28]  A Rosenwald,et al.  Retracted: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) , 2007, Journal of Clinical Pathology.

[29]  S. Yoon,et al.  MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B‐cell lymphoma (DLBCL), especially in germinal centre‐like B cell (GCB) type , 2008, Histopathology.

[30]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Richard Simon,et al.  Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.

[32]  R. Spang,et al.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.

[33]  R. Siebert,et al.  FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. , 2006, The Journal of molecular diagnostics : JMD.

[34]  G. Flandrin,et al.  Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis , 2006, Leukemia & lymphoma.

[35]  R. Campanini,et al.  Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance , 2006, Journal of Translational Medicine.

[36]  P. Sonego,et al.  Mutational status of IgVH genes in B-cell chronic lymphocytic leukemia and prognosis: percent mutations or antigen-driven selection? , 2005, Leukemia.

[37]  Torsten Hothorn,et al.  On the Exact Distribution of Maximally Selected Rank Statistics , 2002, Comput. Stat. Data Anal..

[38]  Emili Montserrat,et al.  Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. , 2003, Blood.

[39]  Axel Benner,et al.  Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.

[40]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[41]  D.,et al.  Regression Models and Life-Tables , 2022 .